Syndax Pharmaceuticals (SNDX) Change in Acquisitions & Divestments (2015 - 2026)

Syndax Pharmaceuticals' Change in Acquisitions & Divestments history runs 12 years deep, the most recent figure standing at $77.8 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 25.7% year-over-year to $77.8 million; the TTM figure through Mar 2026 stood at $459.1 million (up 22.77% YoY), while the FY2025 annual figure was $486.0 million, up 44.1% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $77.8 million, down from $144.8 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $154.9 million in Q2 2023, with the low at $50.4 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $103.0 million (2025), against an average of $99.0 million.
• The sharpest annual moves came in 2022 and 2024: Change in Acquisitions & Divestments surged 149.45% in 2022, then slumped 60.14% in 2024.
• Syndax Pharmaceuticals' Change in Acquisitions & Divestments stood at $113.2 million in 2022, then declined by 0.22% to $113.0 million in 2023, then dropped by 5.01% to $107.3 million in 2024, then jumped by 34.85% to $144.8 million in 2025, then tumbled by 46.27% to $77.8 million in 2026.
• Business Quant data shows SNDX's Change in Acquisitions & Divestments at $77.8 million in Q1 2026, $144.8 million in Q4 2025, and $103.0 million in Q3 2025.